^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
Published date:
03/08/2021
Excerpt:
CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC....A trend toward OS benefit with nivolumab versus placebo was seen in patients with TMB ≥13 mut/Mb (HR, 0.67; 95% CI, 0.45 to 1.01; Fig 3A), but not in those with TMB <13 mut/Mb (HR, 0.92; 95% CI, 0.70 to 1.22; Fig 3B).
DOI:
10.1200/JCO.20.02212
Trial ID:
Test:
Source:
Title:
Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer
Published date:
05/14/2018
Excerpt:
This report evaluated the role of tumor mutation burden in SCLC, and its association with outcomes with dual immune checkpoint blockade. We found that patients with high tumor mutation burden treated with either nivolumab monotherapy or nivolumab plus ipilimumab had improved efficacy compared with those with medium or low tumor mutation burden.
DOI:
10.1016/j.ccell.2018.04.001
